세계의 조산 예방 및 관리 시장 : 기회, 성장 촉진요인, 산업 동향 분석, 예측(2025-2034년)

The Global Preterm Birth Prevention And Management Market was valued at USD 1.8 billion in 2024 and is projected to expand at a CAGR of 7.7% from 2025 to 2034. This remarkable growth is driven by several factors, including rising rates of preterm births, advancements in medical technology, an increasing prevalence of maternal risk factors, and a heightened focus on improving neonatal care.

The market encompasses a range of therapies designed to prevent and manage preterm births, including tocolytic therapy, progesterone therapy, antibiotics therapy, corticosteroid therapy, heparin prophylaxis therapy, and other treatment options. Among these, progesterone therapy is expected to lead the market, growing at a CAGR of 8% and generating USD 1.5 billion by 2034. Progesterone has been extensively studied and proven to significantly reduce the risk of preterm births, particularly in women with a history of spontaneous preterm deliveries or those at high risk. Its proven effectiveness in preventing early labor, especially for women with a short cervix or multiple pregnancies, contributes to its widespread adoption as a primary preventative measure.

The market is also segmented by the route of administration, which includes parenteral, oral, and topical options. The parenteral administration segment is anticipated to experience robust growth, with a projected CAGR of 7.6%, reaching USD 2.7 billion by 2034. Parenteral administration, especially via intravenous (IV) or intramuscular (IM) routes, offers more rapid and efficient delivery of critical drugs like progesterone or tocolytics. This method is essential for high-risk pregnancies, as it bypasses the digestive system, ensuring more consistent and controlled dosing, which makes it a preferred option in clinical settings.

In the U.S., the preterm birth prevention and management market was valued at USD 671.6 million in 2024 and is expected to grow at a CAGR of 7.2% between 2025 and 2034. The U.S. faces a relatively high rate of preterm births compared to other developed nations, creating a pressing need for effective strategies to prevent and manage these early deliveries. This challenge drives the demand for advanced therapies, remedies, and innovative solutions. Furthermore, the U.S. remains a global leader in maternal-fetal medicine research, contributing to the development of cutting-edge technologies and practices designed to prevent and manage preterm births.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of preterm birth
    • 3.2.1.2 Advancements in maternal and fetal care
    • 3.2.1.3 Increased awareness of preterm birth risk factors
    • 3.2.1.4 Rising government initiatives and funding
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Side effects and safety concerns
    • 3.2.2.2 Potential competition from generic drugs
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technology landscape
• 3.6 Pipeline analysis
• 3.7 Gap analysis
• 3.8 Porter's analysis
• 3.9 PESTEL analysis
• 3.10 Future market trends
• 3.11 Value chain analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Therapy Type, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Progesterone therapy
• 5.3 Corticosteroid therapy
• 5.4 Tocolytic therapy
• 5.5 Antibiotics therapy
• 5.6 Heparin prophylaxis therapy
• 5.7 Other therapy types

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Parenteral
• 6.3 Oral
• 6.4 Topical

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Brick and mortar
• 7.3 E-commerce

Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 AbbVie
• 9.2 AMAG Pharmaceuticals
• 9.3 Ferring Pharmaceutical
• 9.4 Merck
• 9.5 Obseva
• 9.6 Pfizer
• 9.7 Takeda Pharmaceutical